Side-by-side · Research reference

DermorphinvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED20/47 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

Dermorphin

Opioid Peptide · μ-Receptor Agonist · Research Only

~30×Morphine potency

μ-selectiveReceptor typeNegri 1992

D-Ala²Unique featureAmiche 1998

Research only · ICV / SC (animal models)

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

Dermorphin

Vesugen

Primary target

μ-opioid receptors (central and peripheral)Negri 1992 Steel 2014

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

N/A — exogenous opioid agonist

Not applicable — does not operate via hormone axis

Origin

Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998 Mignogna 1992

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

Site-directed antibodies produced for detection and purificationCucumel 1996

—

02Dosage Protocols

Parameter

Dermorphin

Vesugen

Legal status

Controlled substance in many jurisdictions · Research only

Not approved for human use.

—

Animal research (ICV)

Low nanomolar to picomolar range

Intracerebroventricular administration in rodent models.

—

Detection limit (doping)

5 pg/mL in equine plasma/urineSteel 2014

High-throughput LC-MS/MS screen developed for racing industry.

—

Duration of action

10–120 minutes (dose-dependent, intrathecal)

—

Evidence basis

Animal studies · In vitro assays

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Human toxicity

Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

Frequency

—

Not specified in available literature

Duration

—

Case series report treatment courses in elderly arterial insufficiency

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

04Side Effects & Safety

Parameter

Dermorphin

Vesugen

Opioid effects

Respiratory depression, sedation, euphoria, tolerance, dependence risk

—

CNS effects

Analgesia (high-affinity sites), catalepsy (low-affinity sites)Negri 1992

—

Kambô ritual toxicity

Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025

—

Peripheral effects

GI motility inhibition (ileum > vas deferens in vitro)Negri 1992

—

Receptor selectivity caveat

Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992

—

Proteolytic stability

Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

Dermorphin

·Human use — not approved by any regulatory authority
·Controlled substance status — possession illegal in many jurisdictions
·Known opioid hypersensitivity or respiratory compromise

Vesugen

—

Relative Contraindications

Dermorphin

·Any context outside approved animal research protocols
·CNS depressant co-administration

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

Dermorphin

Vesugen

1. Legal and ethical framework

Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Animal research protocols

In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Analytical detection

High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Kambô ritual (traditional use)

Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

06Stack Synergy

Dermorphin

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)